CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

AbbVie Inc.

ABBV
$468.20BMega Cap

Next catalyst

Phase 3December 2026

Lutikizumab

Hidradenitis Suppurativa

Get an email about ABBV's next catalysts

Track AbbVie (ABBV) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 35 more upcoming events in our data (Phase 2 readout, Phase 3 readout).See the timeline

Catalyst Timeline

37 upcoming, 5 past

Phase 2

ABBV-400 Phase 2 Est. Readout

December 2026~ABBV-400280

Estimated primary completion for ABBV-400 trial (NCT06107413) in Unresectable Metastatic Colorectal Cancer. Topline data typically follows completion by weeks to months.

Source
Phase 3Next

Lutikizumab Phase 3 Est. Readout (Intrepid)

December 2026~Lutikizumab1,400

Estimated primary completion for Lutikizumab trial (NCT06468228) in Hidradenitis Suppurativa. Topline data typically follows completion by weeks to months.

Source
Phase 2

Venetoclax Phase 2 Est. Readout

December 2026~Venetoclax8

Estimated primary completion for Venetoclax trial (NCT06284486) in Acute Myeloid Leukemia. Topline data typically follows completion by weeks to months.

Source
Data Readout
✓Positive

Data Readout

Jan 1, 2027

Alkermes' orexin drug demonstrated proof-of-concept in ADHD with results anticipated in 2027, while AbbVie advanced AI drug discovery efforts and the FDA expanded use of Eli Lilly's breast cancer medication.

New data for Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma

Source
Phase 2

Liposomal daunorubicin and cytarabine Phase 2 Est. Readout

January 2027~Liposomal daunorubicin and cytarabine172

Estimated primary completion for Liposomal daunorubicin and cytarabine trial (NCT04801797) in Acute Myeloid Leukemia. Topline data typically follows completion by weeks to months.

Source
Phase 3

Livmoniplimab Phase 3 Est. Readout (LIVIGNO-2)

January 2027~Livmoniplimab89

Estimated primary completion for Livmoniplimab trial (NCT06109272) in Hepatocellular Carcinoma. Topline data typically follows completion by weeks to months.

Source
Phase 2

Telisotuzumab Vedotin Phase 2 Est. Readout

February 2027~Telisotuzumab vedotin60

Estimated primary completion for Telisotuzumab Vedotin trial (NCT07323641) in Lung Non-Small Cell Carcinoma. Topline data typically follows completion by weeks to months.

Source
Phase 2

Lutikizumab Phase 2 Est. Readout

February 2027~Lutikizumab180

Estimated primary completion for Lutikizumab trial (NCT06972446) in Rheumatoid Arthritis. Topline data typically follows completion by weeks to months.

Source

How ABBV's past catalysts played out

Market Overview

Stock performance and key metrics

NYSEPharmaceutical PreparationsBiopharmaceutical🇺🇸North AmericaNORTH CHICAGO57.0K employees

AbbVie Inc., also known as AbbVie, is an American pharmaceutical company headquartered in North Chicago, Illinois. AbbVie produces drugs to treat a wide range of medical issues. The company is ranked sixth on the list of largest biomedical companies by revenue. It is ranked 77th on the Fortune 500 and 108th on the Forbes Global 2000. The name "AbbVie" is derived from a combination of "Abbott", the name of its former parent company, with "vie", intended as a reference to a Latin root meaning 'life'.

Website
Drug Pipeline

Estradiol/Norethindrone Acetate

Phase 3

Endometriosis

Risankizumab On-Body Injector (OBI)

Phase 3

Crohn's Disease

Bimatoprost (SR)

Phase 3

Open-Angle Glaucoma

etanercept

Phase 3

Moderate to Severe Plaque Psoriasis

Etentamig

Phase 3

Multiple Myeloma

Acalabrutinib

Phase 3

Chronic Lymphocytic Leukemia

Elagolix

Phase 3

Polycystic Ovary Syndrome

ABT-SLV187

Phase 3

Advanced Parkinson's Disease

ABT-450/r/ABT-267, ABT-333

Phase 3

Chronic Hepatitis C Infection

Paricalcitol

Phase 3

Chronic Kidney Disease Stage 3 and 4

ABT-493/ABT-530

Phase 3

Hepatitis C Virus Infection

sofosbuvir (SOF)

Phase 3

Chronic Hepatitis C Virus

RBV

Phase 3

HCV

Risankizumab SC

Phase 3

Crohn's Disease

Navitoclax

Phase 3

Myelofibrosis (MF)

Tocilizumab

Phase 3

Juvenile Idiopathic Arthritis

Fumaderm

Phase 3

Psoriasis

Fluvoxamine maleate

Phase 3

Obsessive Compulsive Disorder

maxacalcitol

Phase 3

Secondary Hyperparathyroidism

Optimized Medical Treatment

Phase 3

Advanced Parkinson's Disease

Surabgene Lomparvovec (ABBV-RGX-314)

Phase 3

Neovascular Age-related Macular Degeneration

Ranibizumab (LUCENTIS®)

Phase 3

AMD

ABT-712

Phase 3

Chronic Low Back Pain

Ubrogepant

Phase 3

Migraine

Dasabuvir

Phase 3

Chronic Hepatitis C Infection

Palivizumab

Phase 3

Respiratory Syncytial Virus (RSV)

secukinumab

Phase 3

Psoriasis

Telaprevir

Phase 3

Chronic Hepatitis C Infection

Upadacitinib (ABT-494)

Phase 3

Ulcerative Colitis (UC)

AGN-190584

Phase 3

Presbyopia

Topical corticosteroids (TCS)

Phase 3

Atopic Dermatitis

OBV/PTV/r

Phase 3

Chronic Hepatitis C Virus

Botulinum Toxin Type A

Phase 3

Masseter Muscle Prominence

Linaclotide

Phase 3

Functional Constipation (FC)

Ibrutinib

Phase 3

Mantle Cell Lymphoma (MCL)

ABT-267

Phase 3

Chronic Hepatitis C

2 DAA

Phase 3

HCV

Glecaprevir/Pibrentasvir Adult Formulation

Phase 3

Hepatitis C Virus (HCV)

Upadacitinib

Phase 3

Ulcerative Colitis (UC)

ombitasvir/paritaprevir/ritonavir and dasabuvir

Phase 3

Hepatitis C Virus (HCV)

Veliparib

Phase 3

Metastatic Breast Cancer

adalimumab

Phase 3

Pyoderma Gangrenosum

Risankizumab

Phase 3

Crohn's Disease (CD)

Rovalpituzumab tesirine

Phase 3

Small Cell Lung Cancer

ombitasvir/paritaprevir/ritonavir

Phase 3

Hepatitis C Infection

Cariprazine

Phase 3

Depression

ABBV-951

Phase 3

Parkinson's Disease (PD)

BOTOX

Phase 3

Masseter Muscle Prominence

Corticosteroid (CS)

Phase 3

Giant Cell Arteritis (GCA)

Venetoclax

Phase 3

Acute Myeloid Leukemia (AML)

Pegylated Interferon a-2a (PegINF)

Phase 3

Chronic Hepatitis C Infection

ABT-493, ABT-530

Phase 3

Chronic Hepatitis C

Combined Oral Contraceptive

Phase 3

Endometriosis

ABT-530

Phase 3

Chronic Hepatitis C

LUMIGAN

Phase 3

Open-Angle Glaucoma

Optimized antiparkinsonian treatment

Phase 3

Parkinson's Disease (PD)

Lutikizumab

Phase 3

Hidradenitis Suppurativa

Telisotuzumab vedotin

Phase 3

Non-small Cell Lung Cancer

Bimatoprost SR

Phase 3

Open-Angle Glaucoma

ABT-333

Phase 3

Chronic Hepatitis C Infection

Glecaprevir/Pibrentasvir

Phase 3

Hepatitis C Virus (HCV)

Vedolizumab

Phase 3

Ulcerative Colitis

ABT-493

Phase 3

Chronic Hepatitis C

OnabotulinumtoxinA

Phase 3

Forehead Lines

Dalbavancin

Phase 3

Methicillin-Resistant Staphylococcus Aureus

Mirvetuximab Soravtansine

Phase 3

Epithelial Ovarian Cancer

Abatacept

Phase 3

Rheumatoid Arthritis (RA)

Telisotuzumab Adizutecan

Phase 3

Non-Small Cell Lung Cancer

AGN-151586

Phase 3

Glabellar Lines

Atogepant

Phase 3

Chronic Migraine

Best Available Therapy (BAT)

Phase 3

Myelofibrosis (MF)

Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers)

Phase 3

Irritable Bowel Syndrome With Constipation

ABBV-444

Phase 3

Dry Eye Disease

Trifluridine/Tipiracil

Phase 3

Metastatic Colorectal Cancer

Armour Thyroid

Phase 3

Hypothyroidism

ABT-874

Phase 3

Plaque Psoriasis

Antidepressant Therapy (ADT)

Phase 3

Major Depressive Disorder

Estradiol/norethindrone acetate (E2/NETA)

Phase 3

Heavy Menstrual Bleeding

Leuprolide Acetate (LA)

Phase 3

Central Precocious Puberty (CPP)

risankizumab IV

Phase 3

Crohn Disease

Open-label Adalimumab

Phase 3

Axial Spondyloarthritis

Sofosbuvir

Phase 3

Chronic Hepatitis C

ombitasvir/paritaprevir/ritonavir, dasabuvir

Phase 3

Chronic Hepatitis C Virus (HCV Infection Genotype 1)

Topiramate

Phase 3

Migraine

Livmoniplimab

Phase 3

Hepatocellular Carcinoma

Budigalimab

Phase 3

Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma

Cariprazine Flexible Dose

Phase 3

Schizophrenia

ABT-450/r/ABT-267

Phase 3

Hepatitis C Virus Infection

Elotuzumab

Phase 3

Multiple Myeloma

Glecaprevir/Pibrentasvir (GLE/PIB)

Phase 3

Hepatitis C Virus (HCV)

Surabgene Lomparvovec

Phase 3

Diabetic Retinopathy

Tavapadon

Phase 3

Parkinson Disease

ABT-493 coformulated with ABT-530

Phase 3

Hepatitis C Virus Infection

Levodopa-carbidopa intestinal gel

Phase 3

Advanced Parkinson's Disease

Ribavirin (RBV)

Phase 3

Chronic Hepatitis C Virus (HCV) Infection

Levodopa-carbidopa Immediate Release (LC-IR) Tablets

Phase 3

Advanced Parkinson's Disease

Ranibizumab Control

Phase 3

Neovascular Age-related Macular Degeneration

Ombitasvir mini tablet

Phase 3

Chronic Hepatitis C Infection

Paritaprevir mini tablet

Phase 3

Chronic Hepatitis C Infection

Ritonavir mini tablet

Phase 3

Chronic Hepatitis C Infection

Dasabuvir mini tablet

Phase 3

Chronic Hepatitis C Infection

Ribavirin solution

Phase 3

Chronic Hepatitis C Infection

Levodopa carbidopa intestinal gel (LCIG)

Phase 3

Advanced Parkinson's Disease

Glecaprevir + Pibrentasvir Pediatric Formulation

Phase 3

Hepatitis C Virus (HCV)

Folinic acid/Leucovorina

Phase 3

Metastatic Pancreatic Ductal Adenocarcinoma

NOA LIFT

Phase 3

Nasolabial Folds

Dexamethasone (IV)

Phase 3

Lymphoma

Dexamethasone (Oral)

Phase 3

Lymphoma

Upadacitinib Oral Product

Phase 3

Colitis, Ulcerative

Paritaprevir/ritonavir/ombitasvir

Phase 3

Hepatitis C, Acute

Levothyroxine

Phase 3

Hypothyroidism

Nab- Paclitaxel

Phase 3

Non-Small Cell Lung Cancer

Pivekimab Sunirine

Phase 3

Acute Myeloid Leukemia

ABBV-1480

Phase 3

Non-Small Cell Lung Cancer

Elotuzumab (BMS-901608; HuLuc63)

Phase 3

Multiple Myeloma

AGN-193408 SR

Phase 2

Open-angle Glaucoma

MEDI0618

Phase 2

Migraine

ABT-719

Phase 2

Acute Kidney Injury

ABBV-706

Phase 2

Small Cell Lung Cancer

Subcutaneous depot medroxyprogesterone acetate (DMPA-SC)

Phase 2

Endometriosis

ABT-199

Phase 2

Acute Myelogenous Leukemia

ABBV-8E12

Phase 2

Alzheimer's Disease

Erwinia asparaginase

Phase 2

Refractory Acute Lymphoblastic Leukemia

Creon36™

Phase 2

Chronic Pancreatitis

BIIB019 (Daclizumab High Yield Process)

Phase 2

Relapsing-Remitting Multiple Sclerosis

Intrathecal Triples

Phase 2

Refractory Acute Lymphoblastic Leukemia

ABT-072

Phase 2

Hepatitis C Virus Infection

APG777

Phase 2

Atopic Dermatitis

Brimonidine tartrate ophthalmic solution eye drops

Phase 2

Recurrent Ovarian Cancer

Thioguanine

Phase 2

T-cell Acute Lymphoblastic Leukemia

ABBV-8736

Phase 2

Crohn's Disease

Adalimumab-800CW

Phase 2

IBD

Pancreatic Enzyme

Phase 2

Short Bowel Syndrome

Prednisolone acetate ophthalmic suspension eye drops

Phase 2

Recurrent Ovarian Cancer

Calaspargase pegol

Phase 2

T-cell Acute Lymphoblastic Leukemia

Recombinant Granulocyte Colony-Stimulating Factor

Phase 2

Acute Biphenotypic Leukemia

Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)

Phase 2

T-cell Acute Lymphoblastic Leukemia

Trosunilimab

Phase 2

Crohn's Disease

Pegylated interferon (pegIFN)

Phase 2

Chronic Hepatitis C

Ritonavir

Phase 2

Chronic Hepatitis C Infection

ABT-450

Phase 2

Hepatitis C Virus

Emraclidine

Phase 2

Schizophrenia

ABBV-382

Phase 2

Crohn's Disease

ABT-894

Phase 2

Diabetic Neuropathic Pain

ABT-981

Phase 2

Erosive Hand Osteoarthritis

Omaveloxolone

Phase 2

MItochondrial Myopathies

ABT-494

Phase 2

Crohn's Disease

Ranibizumab

Phase 2

Neovascular Age-Related Macular Degeneration (nAMD)

ABT-263

Phase 2

Chronic Lymphoid Leukemia

dexamethasone injection

Phase 2

Hematologic Cancer

ABT-888

Phase 2

Melanoma

ABBV-400

Phase 2

Unresectable Metastatic Colorectal Cancer

rituximab/IDEC-C2B8

Phase 2

Non-Hodgkin Lymphoma (NHL)

ABBV-142

Phase 2

Idiopathic Pulmonary Fibrosis

Onureg + Venetoclax

Phase 2

Untreated Myelodysplastic Syndrome

ABBV-2001

Phase 2

Multiple Myeloma

Ravagalimab

Phase 2

Rheumatoid Arthritis

Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen

Phase 2

Relapsed or Refractory Acute Myeloid Leukemia (AML)

ABT-450/r

Phase 2

Chronic Hepatitis C

ABBV-701

Phase 2

Crohn's Disease

ABT-089

Phase 2

Attention Deficit Hyperactivity Disorder

venetoclax + azacitidine +/- donor lymphocyte infusion

Phase 2

MDS

hydrocodone/acetaminophen extended release

Phase 2

Chronic Low Back Pain

atomoxetine

Phase 2

Attention-Deficit/Hyperactivity Disorder

Elsubrutinib

Phase 2

Systemic Lupus Erythematosus (SLE)

ABT199

Phase 2

Waldenstrom Macroglobulinemia

onabotulinum toxin A

Phase 2

Neuropathic Pain

elezanumab

Phase 2

Multiple Sclerosis (MS)

ABT-869

Phase 2

Advanced Hepatocellular Carcinoma

ABBV-6628

Phase 2

Geographic Atrophy

JAB-3068

Phase 2

Advanced Solid Tumor

ABT-450/ritonavir (r)

Phase 2

Chronic Hepatitis C

Depatuxizumab mafodotin

Phase 2

Glioblastoma

Multiple-dose ATM-AVI, Cohorts 1-4

Phase 2

Gram-negative Bacterial Infection

CVL-865

Phase 2

Seizures

GM-2505

Phase 2

Major Depressive Disorder

PD1 inhibitor

Phase 2

Advanced Solid Tumor

AGN-151607

Phase 2

Post-Operative Atrial Fibrillation

AGN-242428

Phase 2

Dry Eye Disease

ABBV-453

Phase 2

Multiple Myeloma

ABT-122

Phase 2

Rheumatoid Arthritis

TrenibotulinumtoxinE and OnabotulinumtoxinA

Phase 2

Upper Facial Lines

Venetoclax plus Azacitidine

Phase 2

Acute Myeloid Leukemia

JAB-3312

Phase 2

Solid Tumor

Leuprorelin Acetate Depot

Phase 2

Endometriosis

azacitadine

Phase 2

Non-Hodgkin Lymphoma (NHL)

ABBV-932

Phase 2

Generalized Anxiety Disorder (GAD)

ABT-414

Phase 2

Malignant Glioma

Daunorubicin Hydrochloride

Phase 2

Acute Myeloid Leukemia

ABBV-552

Phase 2

Alzheimer's Disease (AD)

Ombitasvir/ABT-450/Ritonavir

Phase 2

Chronic Hepatitis C

ABT-126

Phase 2

Schizophrenia

ABBV-668

Phase 2

Ulcerative Colitis

Topical Steroid

Phase 2

Diabetic Retinopathy (DR)

Venetoclax Oral Tablet

Phase 2

Relapsed Adult AML

Idarubicin Hydrochloride

Phase 2

Acute Myeloid Leukemia

Mitoxantrone Hydrochloride

Phase 2

Acute Myeloid Leukemia

Surzetoclax

Phase 2

Multiple Myeloma

Icalcaprant

Phase 2

Major Depressive Disorder

Tagraxofusp

Phase 2

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

CVL-231

Phase 2

Schizophrenia

ABBV-3067

Phase 2

Cystic Fibrosis

Mirvetuximab Soravtansine-gynx

Phase 2

Ovary Cancer

Lubricating Eye Drops

Phase 2

Recurrent Ovarian Cancer

SYFOVRE

Phase 2

Geographic Atrophy

Alternately treated with VA/low CHA regimen

Phase 2

Intensive Chemotherapy Unfit

AGN-231868

Phase 2

Dry Eye Disease

venetoclax and ibrutinib (I+VEN)

Phase 2

Intermediate Risk Chronic Lymphocytic Leukemia

Atrasentan high dose group

Phase 2

Chronic Kidney Disease

ABT-639

Phase 2

Diabetic Neuropathic Pain

ABT-199 (Main Cohort)

Phase 2

Chronic Lymphocytic Leukemia

ABT-288 High Dose

Phase 2

Cognitive Deficits in Schizophrenia

IMGN632

Phase 2

Acute Myeloid Leukemia

ABT-199 (Safety Expansion Cohort)

Phase 2

Chronic Lymphocytic Leukemia

CVL-871

Phase 2

Apathy in Dementia

AGN-151607-DP

Phase 2

Ventral Hernia

ABT-751

Phase 2

Lung Cancer

Liposomal daunorubicin and cytarabine

Phase 2

Acute Myeloid Leukemia

ABBV-916

Phase 2

Alzheimer's Disease (AD)

TNB-383B

Phase 2

Multiple Myeloma

Revumenib

Phase 2

Acute Myeloid Leukemia

Modified FOLFIRI

Phase 2

Untreated Metastatic Colorectal Cancer

Darigabat

Phase 2

Panic Disorder

IMGN151

Phase 2

Gynecologic Cancers

AGN-151597

Phase 2

Advanced Retinitis Pigmentosa

Oral Levodopa/Carbidopa

Phase 2

Advanced Parkinson's Disease

ABBV-3373

Phase 2

Rheumatoid Arthritis (RA)

Lenvatinib

Phase 2

Hepatocellular Carcinoma

Eluxadoline

Phase 2

Irritable Bowel Syndrome

Panitumumab

Phase 2

Metastatic Colorectal Cancer

ABBV-383 (Etentamig)

Phase 2

Immunoglobulin Light Chain (AL) Amyloidosis

Pneumococcal 13-valent conjugate vaccine (PCV-13)

Phase 2

Rheumatoid Arthritis

Atrasentan

Phase 2

Nephropathy

Fluorouracil infusion

Phase 2

Untreated Metastatic Colorectal Cancer

ABBV-295

Phase 2

Obesity

relapsed/refractory multiple myeloma

2 drugs in this indication

menstrual migraine

2 drugs in this indication

immunology

1 drug in this indication

psoriasis

1 drug in this indication

acute and chronic hepatitis C virus (HCV)

1 drug in this indication

multiple myeloma

1 drug in this indication

HIV/SIV reservoir reduction

1 drug in this indication

anti-wrinkle therapy

1 drug in this indication

frontline non-small cell lung cancer (NSCLC)

1 drug in this indication

Dry Eye Disease

1 drug in this indication

Alzheimer's Disease

1 drug in this indication

relapsed/refractory multiple myeloma (RRMM)

1 drug in this indication

Hepatitis C (acute infection)

1 drug in this indication

Migraine

1 drug in this indication

Open-Angle Glaucoma

1 drug in this indication

oncology

1 drug in this indication

menstrual migraine prevention

1 drug in this indication

Colorectal Cancer (CRC) and Non-Small Cell Lung Cancer (NSCLC)

1 drug in this indication

non-segmental vitiligo

1 drug in this indication

Parkinson's disease

1 drug in this indication

Moderately to Severely Active Crohn's Disease

1 drug in this indication

Inflammatory Bowel Disease (Crohn's disease, ulcerative colitis)

1 drug in this indication

hidradenitis suppurativa (skin disease; abscess burden)

1 drug in this indication

debilitating/painful skin disease (specific condition not named in excerpt)

1 drug in this indication

chronic skin condition

1 drug in this indication

Moderately to severely active Crohn's disease in adults

1 drug in this indication

hidradenitis suppurativa

1 drug in this indication

Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)

Frequently asked questions

What is in AbbVie Inc.'s drug pipeline?→

CatalystAlert tracks 235 drug candidates in AbbVie Inc.'s (ABBV) pipeline across Phase 3, Phase 2. Its lead program is Venetoclax (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is AbbVie Inc.'s next FDA catalyst?→

AbbVie Inc.'s (ABBV) next tracked catalyst is a Phase 3 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track ABBV biotech catalysts?→

Add ABBV to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow AbbVie Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply